Dossier assessment
Icosapent ethyl (hypertriglyceridaemia) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Icosapent ethyl (hypertriglyceridaemia) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Icosapent ethyl (hypertriglyceridaemia) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Reduction of the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (≥ 150 mg/dL [≥ 1.7 mmol/L]) and
- Established cardiovascular disease or
- diabetes mellitus and at least one further cardiovascular risk factor
Added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2022-02-18G-BA documents on this decision
A G-BA decision was published.
Project details
- Project no.
- A21-113
- Commission
- Commission awarded on 01.09.2021 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Addendum
Icosapent ethyl (cardiovascular risk reduction) - Addendum to Commission A21-113
Status: Commission completed